Ocata Therapeutics Company
%20.jpg)
Ocata Therapeutics, Inc. is a clinical stage biotechnology company focused on the development and commercialization of Regenerative Ophthalmology therapeutics. Ocata’s most advanced products are in clinical trials for the treatment of Stargardt’s macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. Ocata’s intellectual property portfolio includes pluripotent stem cell platforms – hESC and induced pluripotent stem cell (iPSC) – and other cell therapy research programs.
Technology:
Regenerative Medicine
Headquarters:
Marlborough, Massachusetts, United States
Funding Status:
M&A
Founded Date:
1-1
Last Funding Type:
Venture - Series Unknown
Investors Number:
13
Estimated Revenue:
$10M to $50M
Employee Number:
11-50
Total Funding:
$82.5M
Industry:
Biotechnology, Health Care, Therapeutics
Investor Type:
For Profit